How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?

被引:122
作者
Fleischmann, Roy [1 ]
van der Heijde, Desiree [2 ]
Koenig, Andrew S. [3 ]
Pedersen, Ronald [3 ]
Szumski, Annette [3 ]
Marshall, Lisa [3 ]
Bananis, Eustratios [3 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Metroplex Clin Res Ctr, Dallas, TX 75231 USA
[2] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands
[3] Pfizer Inc, Dept Specialty Care, Collegeville, PA USA
关键词
DAS28; Rheumatoid Arthritis; Anti-TNF; Disease Activity; TNF-alpha; C-REACTIVE PROTEIN; OF-RHEUMATOLOGY RECOMMENDATIONS; ERYTHROCYTE SEDIMENTATION-RATE; METHOTREXATE THERAPY; ARTHRITIS PATIENTS; 28-JOINT COUNTS; ETANERCEPT; DAS28; COMBINATION; VALIDATION;
D O I
10.1136/annrheumdis-2013-204920
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objectives Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis disease activity; however, values for remission and low disease activity (LDA) for DAS28-CRP have not been validated. American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) guidelines suggest remission should be calculated by Simplified Disease Activity Index (SDAI) rather than DAS28-ESR. We examined values of remission and LDA of DAS28-CRP that correspond to the respective cut-off points for DAS28-ESR and SDAI from five clinical trials. Methods DAS28-CRP cut-offs that best correspond to DAS28-ESR remission <2.6 and LDA 3.2 were obtained by cumulative distribution plots, receiver operating curves and maximum concordance and averaged for each approach, treatment group and study. Level of agreement between DAS28-CRP and DAS28-ESR remission and LDA cut-offs was compared against each other and versus SDAI remission 3.3 and LDA 11. Results Percentage of patients who achieved remission and LDA by DAS28-ESR cut-offs was greater for DAS28-CRP versus DAS28-ESR regardless of patient population or treatment group. Discordance between CRP and ESR cut-offs ranged from 4%-26% and 8%-23% for remission and LDA, respectively, and 19%-40% and 6%-11% for DAS28-CRP versus SDAI, respectively. Estimated (range) remission and LDA thresholds were 2.4 (2.2-2.6) and 2.9 (2.6-3.3), 1.9 (1.6-2.2) and 3.1 (3.1-3.3) and 2.2 (1.1-2.9) and 3.6 (3.4-4.0) for DAS28-CRP versus DAS28-ESR, DAS28-CRP versus SDAI and DAS28-ESR versus SDAI, respectively. Conclusions DAS28-CRP underestimates disease activity when using cut-off points validated for DAS28-ESR; therefore, DAS28-ESR cut-off values should not be applied to DAS28-CRP. Although DAS28-CRP and DAS28-ESR cut-offs for LDA 3.2 correspond to SDAI LDA, neither corresponds well to SDAI remission.
引用
收藏
页码:1132 / 1137
页数:6
相关论文
共 20 条
[1]
Rheumatoid Arthritis Disease Activity Measures: American College of Rheumatology Recommendations for Use in Clinical Practice [J].
Anderson, Jaclyn ;
Caplan, Liron ;
Yazdany, Jinoos ;
Robbins, Mark L. ;
Neogi, Tuhina ;
Michaud, Kaleb ;
Saag, Kenneth G. ;
O'Dell, James R. ;
Kazi, Salahuddin .
ARTHRITIS CARE & RESEARCH, 2012, 64 (05) :640-647
[2]
Measures of Rheumatoid Arthritis Disease Activity Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score With 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score Without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA) [J].
Anderson, Jaclyn K. ;
Zimmerman, Lani ;
Caplan, Liron ;
Michaud, Kaleb .
ARTHRITIS CARE & RESEARCH, 2011, 63 :S14-S36
[3]
Estimated Cutoff Points for the 28-Joint Disease Activity Score Based on C-reactive Protein in a Longitudinal Register of Early Arthritis [J].
Castrejon, Isabel ;
Ortiz, Ana M. ;
Toledano, Esther ;
Castaneda, Santos ;
Garcia-Vadillo, Alberto ;
Patino, Esther ;
Gonzalez-Alvaro, Isidoro .
JOURNAL OF RHEUMATOLOGY, 2010, 37 (07) :1439-1443
[4]
Which Measure of Inflammation to Use? A Comparison of Erythrocyte Sedimentation Rate and C-Reactive Protein Measurements from Randomized Clinical Trials of Golimumab in Rheumatoid Arthritis [J].
Crowson, Cynthia S. ;
Rahman, Mahboob U. ;
Matteson, Eric L. .
JOURNAL OF RHEUMATOLOGY, 2009, 36 (08) :1606-1610
[5]
Two-Year Clinical and Radiographic Results With Combination Etanercept-Methotrexate Therapy Versus Monotherapy in Early Rheumatoid Arthritis [J].
Emery, Paul ;
Breedveld, Ferdinand ;
van der Heijde, Desiree ;
Ferraccioli, Gianfranco ;
Dougados, Maxime ;
Robertson, Deborah ;
Pedersen, Ronald ;
Koenig, Andrew S. ;
Freundlich, Bruce .
ARTHRITIS AND RHEUMATISM, 2010, 62 (03) :674-682
[6]
Felson DT, 2011, ANN RHEUM DIS, V70, P404, DOI [10.1136/ard.2011.149765, 10.1002/art.30129]
[7]
Fransen J, 2003, ANN RHEUM DIS, V62, P151
[8]
Discrepancies in categorizing rheumatoid arthritis patients by DAS-28(ESR) and DAS-28(CRP): can they be reduced? [J].
Hensor, Elizabeth M. A. ;
Emery, Paul ;
Bingham, Sarah J. ;
Conaghan, Philip G. .
RHEUMATOLOGY, 2010, 49 (08) :1521-1529
[9]
Comparison of Disease Activity Score (DAS) 28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values [J].
Inoue, Eisuke ;
Yamanaka, Hisashi ;
Hara, Masako ;
Tomatsu, Taisuke ;
Kamatani, Naoyuki .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (03) :407-409
[10]
Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial [J].
Kim, Ho-Youn ;
Hsu, Ping-Ning ;
Barba, Merle ;
Sulaiman, Wahinnuddin ;
Robertson, Debbie ;
Vlahos, Bonnie ;
Khandker, Rezaul ;
Nab, Henk ;
Freundlich, Bruce ;
Koenig, Andrew .
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2012, 15 (02) :188-196